Serous tubal in situ carcinoma (stic) in primary peritoneal serous carcinomas

International Journal of Gynecological Pathology

Volumn 32, Issue 4, 2013, Pages 339-344

  Horn, Lars Christian ^a   Kafkova, Simona ^a   Leonhardt, Karoline ^a   Kellner, Christin ^a   Einenkel, Jens ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

BRCA; Fallopian tube; p53; Peritoneal cancer; Serous pelvic cancer; Serous tubal carcinoma; STIC

Indexed keywords

KI 67 ANTIGEN; PEROXIDASE; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROUS TUBAL IN SITU CARCINOMA; UTERINE TUBE CARCINOMA; CARCINOMA IN SITU; CYSTADENOCARCINOMA; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PELVIS TUMOR; PERITONEUM TUMOR; UTERINE TUBE; UTERINE TUBE TUMOR;

AGED; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880207822     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31826a629b     Document Type: Article

References (36)

1. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967-75.
2. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo- oophorectomy (RRSO) in BRCA mutation carriers: Experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21:846-51.
3. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:347-51. (Pubitemid 23299731)
4. Mok SC, Schorge JO, Welch WR, et al. Peritoneal tumors. In: Tavassoli FA, Devilee P, eds. WHO Classification of Tumors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:197-202.
5. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-16. Erratum in: Am J Surg Pathol 2010; 34:1891.
6. Crum CP. Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol Oncol 2009;3:165-70.
7. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:4160-5.
8. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007;31:161-9. (Pubitemid 46175016)
9. Leonhardt K, Einenkel J, Sohr S, et al. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 2011;30:417-24.
10. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6. (Pubitemid 43740193)
11. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecol Oncol 2005;98:179-81.
12. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: A descriptive classification. Int J Gynecol Pathol 2008;27:1-9. (Pubitemid 351627965)
13. Mehrad M, Ning G, Chen EY, et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol 2010;17:293-302.
14. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol 2009;22:1133-8.
15. Mehra KK, Chang MC, Folkins AK, et al. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mod Pathol 2011;24:152-6.
16. Maeda D, Ota S, Takazawa Y, et al. Mucosal carcinoma of the fallopian tube coexists with ovarian cancer of serous subtype only: A study of Japanese cases. Virchows Arch 2010;457: 597-608.
17. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: A reproducibility study. Am J Surg Pathol 2011;35:1766-75.
18. Seidman JD, Zhao P, Yemelyanova A. ''Primary peritoneal'' high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011;120:470-3.
19. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: Implications for defining an optimal specimen dissection protocol. Am J Surg Patho 2009;33:1878-85.
20. Schmeler KM, Daniels MS, Soliman PT, et al. Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome. Obstet Gynecol 2010;115(pt 2): 432-4.
21. Lauchlan SC. The secondary Mü llerian system. Obstet Gynecol Surv 1972;27:133-46.
22. Raju U, Fine G, Greenawald KA, et al. Primary papillary serous neoplasia of the peritoneum: A clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989;20: 426-36. (Pubitemid 19134345)
23. Truong LD, Maccato ML, Awalt H, et al. Serous surface carcinoma of the peritoneum: A clinicopathologic study of 22 cases. Hum Pathol 1990;21:99-110. (Pubitemid 20042411)
24. Quezado MM, Moskaluk CA, Bryant B, et al. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol 1999;30:203-7. (Pubitemid 29086953)
25. Chu CS, Menzin AW, Leonard DG, et al. Primary peritoneal carcinoma: A review of the literature. Obstet Gynecol Surv 1999;54:323-35. (Pubitemid 29205395)
26. Lauchlan SC. The secondary mü llerian system revisited. Int J Gynecol Pathol 1994;13:73-9.
27. Horn LC, Bilek K. Frequency and histogenesis of pelvic retroperitoneal lymph node inclusions of the female genital tract. An immunohistochemical study of 34 cases. Pathol Res Pract 1995;191:991-6.
28. Corben AD, Nehhozina T, Garg K, et al. Endosalpingiosis in axillary lymph nodes: A possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol 2010; 34:1211-6.
29. Li J, Abushahin N, Pang S, et al. Tubal origin of 'ovarian' lowgrade serous carcinoma. Mod Pathol 2011;24:1488-99.
30. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 2011;42:918-31.
31. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
32. Chivukula M, Niemeier LA, Edwards R, et al. Carcinomas of distal Fallopian tube and their association with tubal Intraepithelial carcinoma: Do they share a common ''precursor'' lesion? Loss of heterozygosity and immunohistochemical analysis using PAX 2, WT-1, and P53 markers. ISRN Obstet Gynecol 2011;2011:858647.
33. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. (Pubitemid 46092026)
34. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: An immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011;24:1248-53.
35. Kuhn E, Kurman RJ, Vang R, et al. TP53mutations in serous tubal intraepithelial carcinoma and concurrent pelvic highgrade serous carcinoma - evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226:421-6.
36. Holstege H, Joosse SA, van Oostrom CT, et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 2009;69:3625-33.